PPP1R13L and acute myeloid leukemia: To further confirm the predictive role of iASPP in AML, an additional well-defined patient cohort was assessed: samples of 274 patients treated in the HOVON102 trial [24] (EudraCT 2009-011613-24) were available for comparative analysis of iASPP expression patterns and clinical outcome.